ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0079

Treatment Persistence in First-Line Biologic and Targeted Synthetic DMARD Users with Dual-Seropositive RA in the Medicare Population
Abstract Number: 0080

Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in Patients with Rheumatoid Arthritis and Breast Cancer
Abstract Number: 0081

Impact of the COVID-19 Pandemic on Rheumatology Services in a Universal Healthcare Setting in Canada: A Population-based Study
Abstract Number: 0082

Impact of the COVID-19 Pandemic on Healthcare Utilization Among Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients
Abstract Number: 0083

COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Practice Network
Abstract Number: 0084

Facilitators and Barriers of Vaccine Uptake in Patients with Chronic Inflammatory Rheumatic Disease: A Scoping Review
Abstract Number: 0085

Closing the Gender Gap in Global Rheumatology Leadership- Are We There Yet?
Abstract Number: 0086

Patient and Provider Perspectives on Barriers to Communication and Care of Latinx Patients with Lupus and Rheumatoid Arthritis
Abstract Number: 0087

Does Limited English Proficiency Lead to Additional Health Inequity in Medically Vulnerable Populations in Outpatient Rheumatology?
Abstract Number: 0088

Challenges in the Management of Psoriatic Arthritis in Latin America: A Systematic Review
Abstract Number: 0089

Racial Disparities in Rheumatology Clinical Trials
Abstract Number: 0090

Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis
Abstract Number: 0091

Association of Area-Level Heat and Social Vulnerability with Recurrent Hospitalizations Among Individuals with Rheumatic Conditions
Abstract Number: 0092

Characterizing Levels of Specialist Care Received by Patients with Systemic Lupus Erythematosus: Clinical Characteristics, Emergency Care, Hospitalization, and Costs Among Commercially-insured Adults in the United States
Abstract Number: 0093

Comparison of Faculty and Fellow Prescribing Patterns for Rheumatoid Arthritis in an Urban, Academic Hospital

« Previous Page
1
…
7
8
9
10
11
…
154
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].